← Company directoryNASDAQ · SEC EDGAR
Veracyte, Inc.
VCYTA primary-source company identity page built for fast discovery, filing verification and consistent financial research.
SHARE PRICE · INDICATIVE——
A recent price could not be verified. Check the exchange before trading.
ANALYSIS ROUTE
Four checks before any decision
Business model
Understand how the company earns and where demand originates.
Revenue and margin
Compare equivalent periods; separate growth from profitability.
Debt and cash flow
Test balance-sheet resilience and cash conversion.
Valuation and risk
Use sector peers, scenarios and explicit risk limits.
Company calendar
Veracyte Q3 2026 results
Third-quarter financial results from the cancer diagnostics company. The November 4 US post-close window falls on November 5 in Istanbul; revenue, expenses and cash position are in focus.
Veracyte ↗Veracyte Q3 earnings call
Management will discuss third-quarter financial results and provide a general business update. The call will be webcast live through the company's investor relations website.
Veracyte ↗More NASDAQ records
Alphabetically adjacent directory records for faster navigation; this is not a peer or valuation classification.
VCELVericel CorporationNASDAQ · SEC→VCIGVCI Global Limited - Ordinary ShareNASDAQ · SEC→VCREVicore Pharma Holding ABNASDAQ · SEC→VCTRVictory Capital Holdings, Inc.NASDAQ · SEC→VECOVeeco Instruments Inc.NASDAQ · SEC→VEEAVeea Inc.NASDAQ · SEC→VEEAWVeea Inc. - WarrantNASDAQ · SEC→VEEETwin Vee PowerCats Co.NASDAQ · SEC→
DATA STATUS
Open official filings ↗Checking SEC financial statements
A dash means standardized data is unavailable. Always check the filing period, currency and accounting scope.